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Introduction
The first indwelling central venous access catheter was
introduced by Hickman et al. in 1979 which was
subsequently modified and replaced by Broviac catheter.1
Since then, Hickman and Broviac catheters are being used
most commonly.1,2 Central venous access devices are
needed in the management of patients who need
frequent blood products, antibiotics, blood sampling,
prolonged surgical nutrition and chemotherapy.3-5 These
catheters are tunnelled under the skin, but have an
external exit site which require local care and is associated
with a relatively high complication rate.6 Alternative
devices have been developed in the hope of improving
safety and acceptability. One such device is completely
implanted vascular access device (Port-a-Cath)7
commonly called portacath or port which is accessed via
a subcutaneous valve situated in the chest wall. Port-a-
Cath requires less frequent care, gives more freedom and
enables participating in sports.8
Portacath is inserted under general anaesthesia in
children. It is associated with lower complication rate.9-13
In literature, the reported rate of infection of portacath is
15% to 48%,14 blockage is 7-8%,12,15 leak is 3.6% and
dislodgement is 3.6%.12 Other complications are rare. All
published studies have comparable results.6,11 However,
one study showed infection rate of only 3.6%.12 In a local
study, portacath had an infection rate of 50% and parents
of the children had clear preference for portacath over
Hickman line to deliver chemotherapy.16 Studies on the
complications of portacath often have reported
conflicting results.3,5,17,18 This may be due to the variations
in the method of insertion (radiological or surgical) and
the definition of line infection. 
The reported studies cover heterogeneous populations,
but mostly adults. Furthermore, majority of these studies
are done by oncologists and infective complications are
addressed.10,19 In literature, risk factors for portacath
infection are high-risk Acute lymphocytic leukaemia
(ALL), absolute neutrophilic count (ANC), nutritional
status, fever on the day of surgery, induction of
chemotherapy and use of steroids at the time of
induction.20
At our centre, we deal with paediatric leukaemia,
lymphoma and other solid tumours using portacath to
deliver chemotherapy. The first paediatric portacath was
J Pak Med Assoc
1248
ORIGINAL ARTICLE
Implantable port devices in paediatric oncology patients: A clinical experience
from a tertiary care hospital
Sohail Asghar Dogar, Muhammad Arif Mateen Khan
Abstract
Objective: To assess the frequency of infection of portacath in children having malignant tumours and undergoing
chemotherapy, and to assess the association of the infection with already known risk factors. 
Methods: The retrospective review was conducted at Aga Khan University Hospital, Karachi, and involved patient
data related to the period between January 2005 to December 2010. A questionnaire was designed to collect the
required data. A total of 67 children were included having portacath inserted for chemotherapy. Children in which
portacath was inserted under local anaesthesia in Radiology department, reinserted or inserted because of a reason
other than childhood malignancy were excluded. SPSS 19 was used for statistical analysis.
Results: Of the total, 46 (67%) patients were males and a majority of the total (n=31; 46%) was between 6-10 years
of age. Besides, 42 (63%) patients had leukaemia, 7(11%) had lymphoma and 18(26%) had various solid tumours. Six
(8.95%) ports were removed due to infection. There was significant difference between infection and non-infection
groups with respect to absoulute neutrophilic count levels (p <0.001). Positive association was found between low
absoulute neutrophilic count level (<500) and the occurrence of port infection.
Conclusions: Port infection rate is higher in children with low absoulute neutrophilic count. The issue needs to be
addressed and one may have to alter the timings of port insertion. It is recommended to insert port when absoulute
neutrophilic count is normal. To further evaluate the subject, a multicentre trial must be conducted.
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inserted in 2003 at the centre to deliver chemotherapy.
Since then, there has been an increase in the use of
portacath. This study, shares our experience of using
portacath in paediatric oncology patients.
Patients and Methods
The retrospective chart review comprised patient record
from January 2005 to December 2010 at Aga Khan
University Hospital, Karachi. A total of 67 children were
included. In all the patients, ports were inserted electively
by a paediatric surgeon and the position of the tip of the
catheter was confirmed by fluoroscopy. As per routine
platelets and prothrombin time were checked before
insertion. Catheter of size 6 french, gauge of 1.33mm and
length 75 cm was used in younger children of less than 5
years of age. For older children size 7.8 french, gauge
1.6mm and length 75cm was used. Portacath is a closed
system and it is inserted in the internal juglar vein. After
insertion, infusion pumps were used for chemotherapy
with the port. Antibiotic impregnated devices were not
used. Portacath was flushed after every use with normal
saline and if not used, it was flushed with heparinised
saline once a month.
Information regarding the occurrence of infection and
outcome, i.e. whether infection settled with antibiotics
or port was removed due to infection, was collected
from the hospital records. The removed portacaths were
sent for cultures. Basic descriptive statistics were
calculated. Frequency of port infection was calculated
and reported for the patient population as a whole and
for sub-groups such as high-risk ALL, ANC, nutrition
status, fever on the day of surgery, induction of
chemotherapy and use of steroids at the time of
induction. High-risk ALL was labelled on the basis of
histology. ANC (=Total leukocyte count * Neutrophilic
count * 10) of less than 500 was taken as low. Serum
albumin level of <2.5 was taken as poor nutritional
status. Fever on the day of surgery was recorded from
the anaesthesia notes on the day of the surgery.
Similarly, whether chemotherapy was started prior to
portacath insertion or not and whether steroids
(prednisolone) were used or not at the time of induction
of chemotherapy were taken from the records.
SPSS 19 was used for analysis. Descriptive statistics
were calculated like means and standard deviation for
quantitative variables and frequencies and
percentages for qualitative variables. Fisher exact test
was used to assess significant differences between the
groups. Multivariable logistic regression was used to
assess associations of risk factors with infection
occurrence.
Results
A total of 67 ports were inserted in children; majority of
them (n=46; 67%) being males. Overall, 31(46%)
patients were between 6-10 years of age. 42 (63%) had
leukaemia, 7 (11%) had lymphoma and 18 (26%) had
various other solid tumours. Out of 67 ports, 6 (9%)
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Table-1: 
Adjusted OR Unadjusted OR 
OR 95% CI pvalue OR 95% CI pvalue 
ANC 65.222 4.939-861.339 0.002 59.000 6.498-535.741 0.000 
High Risk All 0.305 0.020-4.747 0.397 4.5450 0.807-250596 0.086 
Malnourishment 2.611 0.208-32.739 0.475 0.630 0.107-3.700 0.609 
Fever 1.835 0.099-34.056 0.684 1.156 0.121-11.081 0.900 
Chemo and Steroids 1.058 0.41-27.148 0.973 0.755 0.078-7.321 0.808 
PMDC: Pakistan Medical and Dental Council.
Table-2: 
Journal and 23Paediatric Hematology 22European Journal 14Haemophilia 15Pediatr 17Ann. N.Y. Acad 2151st meeting of American
Posters and Oncology 1989 of Cancer 1996 2000 Surg Int 2002 of  Science 2008 Society  of Haematology 2009
Author Muneef et al Poorter et al Bollard CM et al Spicer et al Z Fadoo et al Oussama Alba 
Swedon Nether-lands New Zealand UK Pakistan et al Canada 
Patients 34 Ports 169 Ports 23 Ports 55 Ports 52 All lines 192 Ports 
Department Oncology Oncology & Surgery Haematology Surgery Onco Haematology 
Population Children Children & Adults Children Children Children Children 
Line Sepsis 44% 2.90% 15.36% 3.60% 50% 6.25%
were removed due to infection. Of these 6 patients, 5
(83%) were males, and in these 5 males, chemotherapy
(with steroid used during induction) had been started
before insertion of port, ANC was less than 500, and
nutritional status (serum albumin <2.5) was poor.
However, none of the patients was febrile on the day of
the insertion of port.
There was significant difference in infection and non-
infection groups with respect to ANC levels (p <0.001).
ANC levels were significant on univariate and
multivariable analysis. Positive association was found
between low ANC level (<500) and infection. There was
a possibility of association of infection with high-risk
ALL and malnourishment due to wider confidence
intervals of odd ratios and positive deviation towards
the right of the null. However, no association of
infection was seen with chemotherapy, steroids or
fever (Table-1).
Discussion
Portacath is quite common in the West, but in Pakistan its
use is rare due to the high cost of the device and the
expertise required to handle it and obviously the
complications that occur as a result of the use. But at our
setup, we use portacath to deliver chemotherapy to
children for a longer period of time. There are specialised
trained nurses that look after the ports.
Portacath is gaining popularity in our oncology patients
over the Hickman line and other central lines. Another
study done showed parents' preference towards
portacath for chemotherapy.16 Portacth is cost-effective
and used throughout the world for chemotherapy in
children. It prevents frequent cannulation and pricks.
Children can participate in sports as well and they have
liberty of movement without fear of the catheter being
pulled out, as there is no exit site.
The infection rate that has been reported in this study
(9%) includes all those ports that have been removed due
to infection, and all those ports in which infection settled
with antibiotics were not included. So, our endpoint was
the removal of port due to infection. The rate of infection
reported from different institutes varies from 3% to 48% in
literature. This difference is due to different definitions of
infection that have been opted for the study12,14,16,21-23
(Table-2).
Infection can be introduced at the time of surgery or
subsequently when portacath is accessed with the
gripper needle. There are standard guidelines for
handling portacath so as to minimise the infection rate
as well as other complications. In this study, all the
infections occurred during the first 2 weeks of the
surgery, signifying that infection may be introduced at
the time of surgery. We do not routinely use pre
operative antibiotics at the time of insertion. Also, role of
pre-operative antibiotics at the time of port insertion is
controversial in literature.
We have only found positive association of port infection
with low ANC. If we inflate the sample size, there is a
possibility of establishing other associations as well. This is
evident from the wide confidence intervals of odd ratios.
A trend of positive deviation towards the right of the null
is seen in cases of high-risk ALL and malnourishment.
However, no trends are seen in other cases
(chemotherapy, steroids or fever). So, there is a possibility
of positive association of infection with high-risk ALL and
malnourishment with the increase in the sample size. In
future, prospective studies shall be designed to establish
these associations.
Conclusion
Port infection rate is higher in children with low ANC. We
need to address this issue and may have to alter the
timings of port insertion. Insertion of port when ANC is
normal is recommended. To further evaluate the problem,
multi-centre trials are needed.
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